**Author details**

Jun Takeda\*, Shintaro Makino and Satoru Takeda Department of Obstetrics and Gynecology, Faculty of Medicine, Juntendo University, Tokyo, Japan

\*Address all correspondence to: jtakeda@juntendo.ac.jp

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**33**

*Hemostasis for Massive Hemorrhage during Cesarean Section*

post-partum haemorrhage (WOMAN): An international, randomised, doubleblind, placebo-controlled trial. Lancet. 2017;**389**:2105-2116. DOI: 10.1016/

[8] Gayet-Ageron A, Prieto-Merino D, Ker K, et al. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: A meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet. 2018;**391**:125-132. DOI: 10.1016/

[9] Ahmadzia HK, Phillips JM, Katler QS,

James AH. Tranexamic acid for prevention and treatment of

[10] Matsunaga S, Takai Y, Seki H. Fibrinogen for the management of critical obstetric hemorrhage. The Journal of Obstetrics and Gynaecology Research. 2018;**45**:13-21. DOI: 10.1111/jog.13788

[11] Takeda J, Takeda S. Management of disseminated intravascular coagulation associated with placental abruption and measures to improve outcomes. Obstetrics & Gynecology Science. 2019;

In press. DOI: 10.5468/ogs.2019

10.1111/jog.12708

[12] Makino S, Takeda S, Kobayashi T, Murakami M, Kubo T, Hata T, et al. National survey of fibrinogen concentrate usage for post-partum hemorrhage in Japan: Investigated by the Perinatology Committee, Japan Society of Obstetrics and Gynecology. The Journal of Obstetrics and Gynaecology Research. 2015;**41**(8):1155-1160. DOI:

[13] Matsunaga S, Takai Y, Nakamura E, Era S, Ono Y, Yamamoto K, et al.

postpartum hemorrhage: An update on management and clinical outcomes. Obstetrical & Gynecological Survey. 2018;**73**:587-594. DOI: 10.1097/ OGX.0000000000000597

S0140-6736(17)30638-4

S0140-6736(17)32455-8

*DOI: http://dx.doi.org/10.5772/intechopen.86394*

[1] Takeda S. Education and training approaches for reducing maternal deaths in Japan. Hypertension Research in Pregnancy. 2018;**6**:15-19. DOI: 10.14390/jsshp.HRP2018-007

[2] Nakabayashi M, Asakura H, Kubo T. Perinatology committee report. Acta Obstetrics and Gynaecology in Japanise.

2007;**59**:1222-1224 in Japanese

[3] Takeda S, Takeda J, Makino S. A minimally invasive hemostatic strategy in obstetrics aiming to preserve uterine function and enhance the safety of subsequent pregnancies. Hypertension Research in Pregnancy. 2019;7. In press. DOI: 10.14390/jsshp.HRP2018-013

[4] Inoue S, Masuyama H, Hiramatsu Y. Multi-Institutional Study Group of Transarterial Embolization for Massive Obstetric Haemorrhage in Chugoku & Shikoku Area Society of obstetrics and Gynecology: Efficacy of transarterial embolisation in the management of postpartum haemorrhage and its impact on subsequent pregnancies. The Australian & New Zealand Journal of Obstetrics & Gynaecology. 2014;**54**(6):541-545. DOI:

10.1111/ajo.12228

HRP2015-008

[5] Takeda S, Makino S, Takeda J, Kanayama N, Kubo T, Nakai A, et al. Japanese clinical practice guide for critical obstetrical hemorrhage (2017 revision). The Journal of Obstetrics and Gynaecology Research. 2017;**43**(10): 1517-1521. DOI: 10.1111/jog.13417

[6] Makino S, Hirai C, Takeda J, Yorifuji T, Itakura A, Takeda S. Hemostatic technique during cesarean section. Hypertension Research in Pregnancy. 2016;**4**:6-10. DOI: 10.14390/jsshp.

[7] WOMEN Trial Collaborators. Effect of early tranexamic acid administration

on mortality, hysterectomy, and other morbidities in women with

**References**

*Hemostasis for Massive Hemorrhage during Cesarean Section DOI: http://dx.doi.org/10.5772/intechopen.86394*
